Últimas noticias sobre Xenetic Biosciences (NASDAQ:XBIO) Bolsa

Xenetic Biosciences

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Xenetic Biosciences Inc

Xenetic Biosciences Inc Warrants (19/07/2024)

XBiotech Inc

Global defense budgets reached unprecedented levels in 2024, driven by mounting conflicts and geopolitical strains. A new report from the Stockholm International Peace Research Institute (SIPRI) showcases a sensational increase in military spending across the globe.
What Happened: According <a href="https://www.sipri.org/media/press-release/2025/unprecedented-rise-global-military-expenditure-european-and-middle-east-spending-surges">to</a> SIPRI, military expenditure rose 9.4% to $2.72 trillion. This marks the most drastic annual increase since the Cold War concluded. All regions reported higher defense outlays, with Europe and the Middle East demonstrating particularly speedy growth. 
More than 100 nations enhanced their military budgets, often reallocating funds from other crucial sectors. U.S. military expenditure touched $997 billion, making up 66% of NATO&#8217;s total and 37% of global defense spending.
See Also: <a href="https://www.benzinga.com/news/25/04/44889497/its-offensive-and-just-plain-wrong-trumps-budget-proposal-to-eliminate-head-start-affecting-over-1-million-parents">&#8216;It&#8217;s Offensive And Just Plain Wrong&#8217;—Trump&#8217;s Budget Proposal To Eliminate Head Start, Affecting Over 1 Million Parents</a>
Why It Matters: Europe&#8217;s military expenditure, including Russia, soared 17%, moving past Cold War-era numbers. Russia&#8217;s defense budget alone rose by 38% to an approximate $149 billion, making up 7.1% of its Gross Domestic Product. 
Ukraine, despite major financial difficulties, increased military spending by 2.9% to $64.7 billion, with its defense budget now taking up all available tax revenue.
The report underscores rising concerns about the long-term impact of prioritizing military budgets over social and economic necessities. 
SIPRI warns that the trend could restructure societies for decades to come. In Europe, the ongoing war in Ukraine and ambiguity surrounding U.S. NATO support have prompted increased defense spending.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45030778/trump-running-american-economy-like-a-mafia-don-economist-craig-shapiro-draws-parallels-with-russias-president">Trump Running American Economy Like A &#8216;Mafia Don&#8217;: Economist Craig Shapiro Draws Parallels With Russia&#8217;s President</a></li>
</ul>
Image via Shutterstock

News

Global

Economics

General

Global Defense Budgets Surge To $2.7 Trillion As Europe And Middle East Lead Steepest Increase Since Cold War: Report

Buybacks

MIELY

Mitsubishi Electric Launches Share Buyback Program For 60M Shares Worth Up To JPY 100B

In a recent private event,&nbsp;Donald Trump Jr., son of the U.S. President, voiced his support for enhanced business cooperation with Eastern Europe.
What Happened: Trump Jr. underscored his close connections to the region during his address at the Trump Business Vision 2025 event organized by businessman Zoltán Aczél and Portfolio at Budapest, Hungary. He spotlighted his Czechoslovakian roots and language proficiency owing to his mother late Ivana Trump, and applauded the region&#8217;s dramatic evolution over the past five decades, <a href="https://www.portfolio.hu/en/economy/20250425/donald-trump-jr-we-want-to-do-a-lot-of-good-business-with-our-friendly-allies-757309">reported</a> Portfolio.
As the&nbsp;Executive Vice President of the&nbsp;Trump Organization, Trump Jr. praised Hungary&#8217;s robust political leadership, specifically Prime Minister Viktor Orbán. He expressed belief in the potential for successful collaboration between American and Hungarian businesses.
He is hopeful that the U.S.-Eastern Europe ties would generate a lot of business amid threats facing the U.S., Hungary and the Central and Eastern European region.
&#8220;I understand the threat that looms from so many places and it&#8217;s not the evil boogeyman of Russia, but likely China,&#8221; pointed out the U.S. President&#8217;s son. 
Trump Jr. recognized the necessity to diversify the U.S. economy&#8217;s dependencies, pointing out the high concentration of pharmaceutical production in China and advanced chip technology in Taiwan. He proposed that Eastern Europe, with its committed workforce and lower labor costs, could assume many activities currently outsourced to China.
&#8220;Pulling away from China is the first step, the dependence is too high,&#8221; stated Trump Jr.
SEE ALSO:&nbsp;<a href="https://benzinga.com/general/sports/25/04/45027895/why-shaq-wont-share-his-500-million-fortune-with-his-kids-we-aint-rich-im-rich-im-not-going-to-hand-it-to-you-you-gotta-earn-it" target="_blank" rel="noreferrer noopener">Why Shaq Won't Share His $500 Million Fortune With His Kids: ‘We Ain't Rich. I'm Rich. I'm Not Going to Hand It to You, You Gotta Earn It&#8217; &#8211; Benzinga</a>
Why It Matters: This comes at a time when the U.S. is experiencing strained relations with China. The ongoing trade war with China has led to a significant decrease in U.S. imports <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">from the</a> Asian nation, while China&#8217;s Ministry of Commerce has <a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis">denied rumors</a> of ongoing trade discussions with the U.S.
Against this backdrop, analysts suggest there are concerns that China <a href="https://www.benzinga.com/news/global/25/04/44892820/xi-jinping-could-woo-europe-with-a-potential-china-deal-to-undercut-trumps-tariff-strategy-expert-warns">might leverage</a> the strained U.S.-EU relations to its benefit, leading Beijing to shift the majority exports to Europe.
Trump Jr.&#8217;s call for increased cooperation with Eastern Europe could be seen as a strategic move to diversify the U.S.&#8217;s economic dependencies amid these ongoing tensions. Despite not being a member of the Trump administration, Trump Jr. was hopeful about the renewal of the expired double tax treaty between the U.S. and Hungary, citing the strong relationship between his father, Donald Trump and Prime Minister Orbán.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45022796/this-is-not-really-how-i-pictured-my-life-at-30-air-force-vet-says-he-works-retail-for-18-an-hour-and-feels-" target="_blank" rel="noreferrer noopener">&#8216;This Is Not Really How I Pictured My Life At 30&#8217;—Air Force Vet Says He Works Retail For $18 An Hour And &#8216;Feels Like A Loser&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Trump Jr. Leans On His Czech Roots To Boost US-Eastern Europe Ties While 'Pulling Away' From China: 'It's Not The Evil Boogeyman Of Russia, But Likely China'

Consolidated Financial Results Revenue: 5,521.7 billion yen (5% increase year-on-year) Operating profit: 391.8 billion yen (19% increase year-on-year) Profit before income taxes: 437.2 billion yen (20% increase year-on-year) Net profit attributable to Mitsubishi Electric Corp. stockholders: 324.0 billion yen (14% increase year-on-year)

Earnings

Mitsubishi Electric's FY25 Revenue ¥5.521T, Up 5% YoY; Net Profit Attributable To Stockholders ¥324B, Up 14% YoY

CRWD

CrowdStrike Redefines Cybersecurity With Autonomous Charlotte AI Agentic Platform

SYNA

Synaptics Expands Veros Lineup With First Wi-Fi 7 SoCs Tailored For High-Performance, Low-Power IoT Applications

Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/ROP/earnings">opening bell on Monday, April 28.</a>
Analysts expect the Sarasota, Florida-based company to report quarterly earnings at $4.74 per share, up from $4.41 per share in the year-ago period. Roper Technologies projects to report quarterly revenue at $1.88 billion, compared to $1.68 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 24, Roper Technologies disclosed a deal to acquire CentralReach from Insight Partners for a net purchase price of around $1.65 billion.
Roper Technologies shares fell 0.4% to close at $557.70 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/rop/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Stephen Tusa maintained a Neutral rating and cut the price target from $558 to $465 on April 8, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Brad Reback initiated coverage on the stock with a Buy rating and a price target of $685 on March 27, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Oppenheimer analyst Christopher Glynn maintained an Outperform rating and raised the price target from $630 to $640 on Jan. 31, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Raymond James analyst Brian Gesuale reiterated a Strong Buy rating and increased the price target from $620 to $655 on Jan. 31, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Barclays analyst Julian Mitchell maintained an Underweight rating and cut the price target from $569 to $562 on Jan. 8, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying ROP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png" alt="" class="wp-image-890254" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Roper Technologies Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<ul>
<li>TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients</li>
<li>TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients</li>
<li>Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events</li>
<li>On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025</li>
<li>Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET</li>
</ul>

TARA

Reported Saturday, Protara Therapeutics Shares Interim Results Highlighting Durable Clinical Responses With TARA-002 In High-Risk NMIBC

The authorities initially prioritized vaccination of adults aged 65 and over, especially those with comorbidities. On April 25, the French health authorities decided to suspend the use of IXCHIQ&#xAE; in persons aged 65 years and older pending further investigation. This is a response to an ongoing investigation of three cases of SAEs resulting in hospitalization, including one death, after vaccination with IXCHIQ&#xAE; among people in La Reunion. The three individuals who were hospitalized were over 80 years old and had pre-existing comorbidities3. These SAEs were reported through the pharmacovigilance system set up by the French health authorities, and causality has not been definitively established. The HAS maintains its current recommendation for IXCHIQ&#xAE; for people aged 18 to 64 years old as part of the ongoing vaccination campaign.

VALN

Reported Saturday, Valneva Provides Update On IXCHIQ Chikungunya Vaccine Use Following HAS Recommendation And Safety Investigation

<ul>
<li>Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone</li>
<li>Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years</li>
<li>Results have been shared with global health authorities to support potential regulatory filings</li>
</ul>

Reported Saturday, Pfizer's Sasanlimab Combination Therapy Shows Strong Event-Free Survival Gains In High-Risk Non-Muscle Invasive Bladder Cancer

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy
95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population

Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival

<ul>
<li>Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C</li>
<li>58.3% of patients showed durable complete responses by K-M at 24 months</li>
<li>97.3% of all treated patients remained free from progression to MIBC at 24 month</li>
<li>91.6% of responders remained cystectomy-free at 24 month</li>
<li>No Grade 3 or greater treatment-related adverse events or deaths reported</li>
<li>Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M</li>
<li>Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025</li>
</ul>

CGON

Reported Saturday, CG Oncology Reports Durability In BOND-003 Cohort C And Encouraging Early Results In Cohort P For Cretostimogene Grenadenorepvec

A man has become the first non-verbal, as well as only the third person ever, to receive a Neuralink Brain-Chip Interface (BCI) implant.
What Happened: Author Bradford G Smith suffers from ALS or Amyotrophic Lateral Sclerosis, a very rare nervous system disease that severely impacts motor functions. Smith released a video on the social media platform X to share the update on Sunday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am the 3rd person in the world to receive the <a href="https://twitter.com/neuralink?ref_src=twsrc%5Etfw">@Neuralink</a> brain implant. 1st with ALS. 1st Nonverbal. I am typing this with my brain. It is my primary communication. Ask me anything! I will answer at least all verified users! Thank you <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>! <a href="https://t.co/bxYO3SBfA2">pic.twitter.com/bxYO3SBfA2</a>
&mdash; Bradford G Smith (Brad) (@ALScyborg) <a href="https://twitter.com/ALScyborg/status/1916630186382291242?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Smith says that he uses the Neuralink implant to control the cursor on his laptop as well as Grok AI to create a clone of his own voice to speak. The video Smith shared was also edited by the BCI chip.
Why It Matters: The news comes as Elon Musk has touted his Neuralink BCI as technology that will help completely <a href="https://www.benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes">blind people see again</a>, the billionaire shared.&nbsp;&nbsp;
Musk also reiterated that robots would <a href="https://www.benzinga.com/25/04/45031447/elon-musk-says-the-best-human-surgeons-have-just-five-years-before-robots-overtake-them-reveals-instance-when-neuralink-had-to-use-a-robot-for-task-impossible-for-a-human">outperform human surgeons</a> in almost 5 years. He said Neuralink "had to use a robot for the brain-computer electrode insertion, as it was impossible for a human to achieve the required speed and precision."
Elsewhere, Neuralink is also eyeing an<a href="https://www.benzinga.com/general/biotech/25/04/44972585/elon-musks-neuralink-eyes-8-5-billion-pre-money-valuation-in-latest-funding-round-report"> $8.5 billion pre-money valuation</a> in its latest round of funding as the company aims to raise over $500 million, in ongoing talks with investors.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk&#8217;s Brain Chip</a></li>
</ul>
Image Via Shutterstock

Biotech

Tech

Man Battling ALS Becomes First Non-Verbal Patient To Receive Elon Musk's Neuralink Brain Implant

As AI chatbots like OpenAI's ChatGPT, Anthropic's Claude, and Perplexity reshape how users search for information, brands are adjusting their strategies to maintain visibility in this new search environment, which is increasingly displacing traditional search engines like Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: In a shift that threatens Google's dominance, brands are adopting new strategies to ensure they remain visible in the results generated by AI chatbots, <a href="https://www.ft.com/content/9cc6cc0b-759f-4b8e-9ed1-9e32ad0fe22f">reported</a> the Financial Times on Sunday.
Instead of clicking through to websites, many users now rely on AI's synthesized responses, which have decreased web traffic by up to 25%, the report noted, citing research from consultancy Bain.
Taking cognizance of this development, companies like Brandtech and Profound have developed tools that monitor how often brands appear in AI-driven responses, providing insights on how businesses can optimize for these models.
See Also: <a href="https://www.benzinga.com/25/04/44982688/alphabet-q1-earnings-preview-google-parent-stock-at-fork-in-the-road-while-antitrust-concerns-remain" target="_blank" rel="noreferrer noopener">Alphabet Q1 Earnings Preview: Google Parent Stock At ‘Fork In The Road,' While Antitrust Concerns Remain</a>
"This is about much more than just getting your website indexed in their results. This is about recognizing large language models as the ultimate influencer," said Jack Smyth, partner at Brandtech.
Brandtech has developed a &#8220;Share of Model&#8221; tool that helps brands analyze their visibility in AI search results and provides recommendations for optimizing website text and images.&nbsp;
Profound, which secured $3.5 million in seed funding in August, led by Khosla Ventures, offers a data analytics platform that enables brands to monitor popular industry queries and assess their standing within AI search results, the report said.
Why It's Important: On Thursday, Alphabet <a href="https://www.benzinga.com/25/04/44995955/alphabet-q1-earnings-highlights-google-search-youtube-cloud-show-robust-momentum">posted first-quarter revenue</a> of $90.23 billion, a 12% rise compared to the same period last year, beating Wall Street's expectation of $89.2 billion. Revenue from Google Search reached $50.7 billion, up from $46.2 billion a year earlier.
&nbsp;The strong performance helped ease investor concerns about rising competition from AI chatbots like Elon Musk's Grok and fears that Google's own Gemini chatbot and AI-generated summaries might be cutting into its traditional ad-driven search traffic, the report said.
Deepwater Asset Management's Gene Munster previously said that Google's existing search format, which blends AI overviews, blue links, and organic results, <a href="https://www.benzinga.com/25/04/44999838/can-google-adapt-like-amazon-or-will-it-face-ebays-fate-gene-munsters-candid-take-on-the-search-giants-path-forward-in-the-age-of-ai">may fall short against newer</a>, more streamlined search experiences offered by models like Grok, ChatGPT, and Claude.
Price Action: In after-hours trading, Alphabet Inc.&#8217;s Class A shares slipped 0.16% to $161.70, while Class C shares dipped 0.1% to $163.68, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Alphabet holds a growth score of 64.44%, based on Benzinga Edge Stock Rankings. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it compares to other companies</a> in the sector.
Photo Courtesy: Ascannio On Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44986406/if-you-invested-1000-in-google-stock-when-it-acquired-youtube-heres-how-much-youd-have-today" target="_blank" rel="noreferrer noopener">If You Invested $1,000 in Google Stock When It Acquired YouTube, Here's How Much You'd Have Today</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Media

GOOG

GOOGL

Google Faces Growing Threat As Chatbots Reshape How Users Search For Brands: Are ChatGPT, Claude And Others AI Bots Set To Be The 'Ultimate' Influencers?

Chinese manufacturers are suspending operations and pursuing alternative markets as U.S. tariff increases take effect, creating ripple effects across global supply chains and threatening millions of jobs.
What Happened: Chinese factories are pausing production due to the impact of U.S. tariffs, as <a href="https://www.cnbc.com/2025/04/28/chinese-factories-stop-production-eye-new-markets-as-us-tariffs-hit.html?ref=biztoc.com">reported</a> by CNBC on Monday. The lost orders are affecting jobs and prompting Chinese exporters to explore new sales strategies, such as livestreaming at home.
According to Cameron Johnson, a senior partner at consulting firm Tidalwave Solutions, factories producing toys, sporting goods, and low-cost Dollar Store-type goods are currently the most affected. &#8220;While not large-scale yet, it is happening in the key [export] hubs of Yiwu and Dongguan, and there is concern that it will grow,&#8221; Johnson said. The impact of recent tariff hikes exceeding 100% is &#8220;way bigger&#8221; than the COVID-19 pandemic&#8217;s disruption, says Ash Monga, CEO of Imex Sourcing Services. 
Woodswool, an athleticwear manufacturer near Shanghai, reports all U.S. orders have been canceled, with over half its production once destined for American customers. The company has pivoted to domestic sales through Baidu&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) livestreaming platform, though its new sales channel generates only modest revenue.
See Also: <a href="https://www.benzinga.com/25/04/44999959/how-the-us-china-trade-war-is-unintentionally-boosting-demand-for-intels-older-chips-amid-economic-uncertainty">Intel&#8217;s Older Parts Are In Demand Thanks To US-China Trade War: &#8216;Tariffs Have Everybody Hedging Their Bets,&#8217; Says Executive</a>
Why It Matters: Many companies are diversifying production to India over Southeast Asia, while others are turning from U.S. customers to those in Europe and Latin America. Some companies have already built businesses on other trade routes from China.
For U.S. investors, these developments signal potential disruption in supply chains and pricing. Goldman Sachs has downgraded China&#8217;s Gross Domestic Product growth <a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns?utm_source=chatgpt.com">forecasts to 4.0% for 2025 and 3.5% for 2026</a>, below the government&#8217;s 5% target.
The U.S.-China trade war, under President Donald Trump&#8216;s administration, has led to a <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">significant decrease in U.S. imports </a>from China. In response, China has started to<a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts"> exempt some U.S. imports</a> from high tariffs, indicating a possible easing of trade tensions.
The iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>), a widely followed U.S.-listed fund that tracks major Chinese companies, has fallen 4.38% since Trump introduced a 34% &#8220;reciprocal&#8221; tariff on Chinese imports.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45005825/us-has-tons-of-solutions-to-secure-rare-earth-production-if-china-halts-exports-experts-say-but-warn-of-significant-challenges">US Has &#8216;Tons Of Solutions&#8217; To Secure Rare Earth Production If China Halts Exports, Experts Say, But Warn Of Significant Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

BIDU

Trump Tariffs Prompt Suspension Of Chinese Factory Operations And Shift To New Markets

<ul>
<li>Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as&nbsp;a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to&nbsp;the U.S. Food and Drug Administration</li>
</ul>

Reported Saturday, Medtronic's Hugo RAS System Achieves 98.5% Surgical Success Rate In Largest U.S. Robotic-Assisted Urology Study

<ul>
<li>One-year clinical trial data for the next-generation, investigational, Sphere-360&#x2122; single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib</li>
<li>Dual-energy (RF/PF), focal Sphere-9&#x2122; catheter demonstrates efficacy for linear ablation in persistent AFib</li>
<li>Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting</li>
</ul>

Reported Saturday, Medtronic's Affera Sphere-360 Catheter Demonstrates Safety And Performance Results For Paroxysmal AFib

Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly considering a shift of iPhone assembly to India. However, a renowned analyst has expressed skepticism about the potential effectiveness of this move in mitigating the impact of China tariffs.
What Happened: Craig Moffett, a partner and senior managing director at MoffettNathanson, questioned the feasibility of Apple&#8217;s plans on Friday. He argued that the shift to India wouldn&#8217;t significantly reduce costs related to tariffs, though it would help to some extent, as iPhone components would still be manufactured in China, <a href="https://www.cnbc.com/2025/04/26/apple-iphone-assembly-in-india-wont-cushion-china-tariffs-moffett.html">reported</a> CNBC.
&#8220;You have a tremendous menu&nbsp;of problems created by tariffs,&nbsp;and moving to India doesn&#8217;t&nbsp;solve all the problems,&#8221; Moffett told CNBC&#8217;s &#8220;Fast Money&#8221;. &nbsp;"I would question how that's going to work,&#8221; stated the analyst. 
He added that a trade war impacts both the cost of goods and demand and iPhone may face issues on the latter.
Last week, in a note to clients, MoffettNathanson reasoned that India has enough capacity to fulfill up to half of the U.S. demand for iPhones. Moreover, as the parts would still be from China, there remains an uncertainty over whether the iPhones would face Indian or Chinese tariff rates — or possibly an expensive mix of both.
Moffett told CNBC that the backlash against Apple in China, triggered by U.S. tariffs, will negatively impact iPhone sales. "Volumes are really going to the Huaweis and the Vivos and the local competitors in China rather than to Apple,&#8221; stated the analyst. 
Moffett points out that Apple also isn't receiving support from its carriers AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), and T. Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) to help soften the impact of tariffs, after they declared that they won&#8217;t be absorbing the additional costs of tariffs on handsets.
Moffett slashed his price target on Apple stock on Apr 21 to $141 from $184 a share.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/45029504/elon-musks-ex-wives-missed-out-on-his-billion-dollar-wealth-heres-why" target="_blank" rel="noreferrer noopener">Elon Musk's Ex-Wives Missed Out on His Billion-Dollar Wealth — Here's Why &#8211; Benzinga</a>
Why It Matters: This skepticism on the heels of previous week&#8217;s report that&nbsp;Apple plans to import most of the iPhones&nbsp;it sells in the U.S. <a href="https://www.benzinga.com/25/04/45014074/apple-plans-iphone-shift-from-china-to-india-amid-tariff-pressures-geopolitical-risks">from India</a> by the end of 2026. This would require the company to double its annual iPhone output in India to over 80 million units.
UBS analyst David Vogt <a href="https://www.benzinga.com/25/04/44973883/analysts-slash-aapl-stock-price-target-amid-anticipated-tariffs-supply-chain-concerns-a-lose-lose-choice">lowered his price target&nbsp;</a>for Apple from $236 to $210 in anticipation of widespread tariffs. Vogt noted that Apple seemed to have expedited the shipment of around one million iPhones, leading to a year-over-year rise in iPhone revenue for the March quarter.
That being said, Moffett is not completely bearish on the iPhone maker. "I think quite highly of Apple. My concern about Apple has been the valuation more than the company."
Benzinga&#8217;s Edge Rankings&nbsp;highlight strong momentum and quality rankings for Apple in the 76th and 85th percentiles, respectively. Curious how other stocks stack up?&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Click here</a>&nbsp;to uncover growth and momentum scores for top stocks.
Over the past month, Apple stock declined nearly 4%, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45017261/bitcoin-mining-costs-jump-to-137000-per-coin-when-accounting-for-non-cash-expenses-coinshares" target="_blank" rel="noreferrer noopener">Bitcoin Mining Costs Jump To $137,000 Per Coin When Accounting For Non-Cash Expenses: CoinShares &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

TMUS

Analyst Casts Doubt On Apple's Reported Move To Shift iPhone Production To India Amid Rising China Tariff Pressures: 'Doesn't Solve All The Problems'

<ul>
<li>KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC)</li>
<li>Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program</li>
</ul>

Reported Sunday, Merck's Phase 3 KEYNOTE-689 Data Shows KEYTRUDA Significantly Improves Event-Free Survival As Perioperative Therapy In Locally Advanced Head And Neck Cancer

The Nasdaq has staged a remarkable turnaround in April, transforming from what was initially dubbed the &#8220;worst April for the stock market since the Great Depression&#8221; to posting gains for the month, a recovery that&#8217;s drawing attention from prominent market analysts.
What Happened: On Sunday, Tom Lee, Head of Research at Fundstrat Global Advisors, endorsed Treasury Secretary Scott Bessent&#8216;s observation about the market&#8217;s resilience, describing the equity recovery as a &#8220;White House put&#8221; – suggesting government policies are providing a floor for market values.
&#8220;Equity recovery cannot be ignored,&#8221; Lee wrote on X, responding to Bessent&#8217;s post highlighting the dramatic shift in market narrative.
The S&amp;P 500 index, tracked by SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has gained 10.89% since its April 8 low of 4,982, currently trading around 5,525. This recovery follows concerns over potential tariff impacts and recession risks that had previously shaken investors. Meanwhile, the Nasdaq 100, tracked by Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), has surged 13.70% from its low of 17,090 on the same day, now trading at 19,432.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f440;&#x1f440;&#x1f440; &#x1f447; Agree &#x1f4af;&#x1f4af;&#x1f4af;&#x1f4af; Equity recovery cannot be ignored PS: This is also known as a "White House" put<a href="https://twitter.com/hashtag/sundayvibes?src=hash&amp;ref_src=twsrc%5Etfw">#sundayvibes</a> <a href="https://t.co/5rXpcLFYHb">https://t.co/5rXpcLFYHb</a>
&mdash; Thomas (Tom) Lee (not drummer) FSInsight.com (@fundstrat) <a href="https://twitter.com/fundstrat/status/1916562502281810374?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The rebound contrasts sharply with warnings from analysts like Chris Senyek of Wolfe Research, who recently cautioned that the S&amp;P 500 could plunge as low as 3,700 points – a potential 37% decline from January levels – if tariff-related uncertainty <a href="https://www.benzinga.com/markets/equities/25/04/45004528/sp-500-could-crash-37-to-3700-if-tariff-fallout-triggers-recession-warns-wolfe-research">triggers a recession in 2025</a>.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45031324/bitcoin-ethereum-dogecoin-drop-as-stock-futures-slide-willy-woo-says-all-dips-are-for-buying-with-btc-eyeing-all-time-highs">Bitcoin, Ethereum, Dogecoin Drop As Stock Futures Slide: Willy Woo Says &#8216;All Dips Are For Buying&#8217; With BTC Eyeing &#8216;All-Time Highs</a>
Why It Matters: Market volatility has been exacerbated by President Donald Trump&#8216;s tariff announcements in early April, particularly regarding China. Despite the president&#8217;s recent statements that he would maintain tariffs without &#8220;substantial&#8221; concessions from Beijing, markets have shown surprising resilience.
Technical analysts remain cautious about the sustainability of the recovery. JPMorgan&#8216;s Jason Hunter has identified the 5,425-5,650 range as key resistance for the S&amp;P 500, <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45011336/sp-500-magnificent-7-hit-resistance-analyst-warns-of-more-pain-before-gain">suggesting the index could retreat to 4,500-4,800</a> before establishing a &#8220;more durable bottom.&#8221;
The &#8220;Magnificent 7&#8221; tech stocks that have driven much of the market&#8217;s performance in recent years are &#8220;consolidating within volatile ranges below their respective breakdown levels,&#8221; according to Hunter, indicating <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45011336/sp-500-magnificent-7-hit-resistance-analyst-warns-of-more-pain-before-gain">potential challenges ahead for market leaders</a> including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Photo: JHVEPhoto / Shuttesstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Chamath Palihapitiya Says Nvidia Is Huawei&#8217;s &#8216;New Target&#8217; — A &#8216;National Champion&#8217; That Crushed Tech Giants With A &#8216;Low-End Disruptor&#8217; Strategy</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

MSFT

NVDA

Tom Lee Backs Scott Bessent 'White House Put' Theory As Nasdaq Flips From Worst April Start Since Great Depression To Major Comeback

Press Releases

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Comments

Xenetic Biosciences

Noticias

Últimas noticias sobre Xenetic Biosciences (NASDAQ:XBIO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL